VRDN Viridian Therapeutics Inc Total Asset Value of Company

This price evolution chart on GURU.Markets shows that the total assets of Viridian Therapeutics (VRDN) amount to 839.83. The business relies on creating enhanced versions of popular drugs, focusing on antibodies for eye and thyroid therapies. The development of multiple promising drugs minimizes the probability of trial failure. The quality of biomolecules is guaranteed through the use of specialized transport systems with strict temperature control.

VRDN (Viridian Therapeutics) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Viridian Pharma (VRDN)

- stock quotes and analyst forecast:

Share Price viridiantherapeutics.com|VRDN - Price Target Chart

- market capitalization data:

Market Valuation Viridian Corp|VRDN - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Viridian Therapeutics|VRDN - Book Capitalization|Market Capitalization to Book Value Ratio viridiantherapeutics.com|VRDN - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Viridian Therapeutics|VRDN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Viridian Corp|VRDN - Company Aggregate Debts|Debts to Book Capitalization Viridian Corp|VRDN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Viridian Therapeutics|Immediate Liquidity viridiantherapeutics.com

- net income and valuation multiples indicators:

VRDN - Net Income

Fundamental valuation:Viridian Therapeutics

Manufactured products of Viridian Therapeutics

To find a balance between cost and business quality, it is essential to consider the total resources calculated reversely via ROA as the sum of equity and debt capital. This metric reflects the scale of the material base of Viridian Therapeutics (VRDN), where the company's volume of financial assets confirms the ability of this promising developer of targeted biologics for eye treatment to maintain high innovation intensity and operational resilience.

Key competitors

Total Business Assets ALC|Aggregate Company Assets Bausch + Lomb|Glaukos Corp - Total Asset Value of Company|Company Total Assets APLS|BLTE (Belite Bio Inc) - Aggregate Asset Value|Company Total Assets OCUL (Ocular Therapeutix)|Company Total Assets harrowinc.com HROW|LENZ - Aggregate Company Assets|Aggregate Asset Value OCS (oculis.com)|EyePoint Pharma (EYPT) - Aggregate Company Assets|Cumulative Company Assets Kodiak Corp|ALDX (Aldeyra Therapeutics Inc.) - Company Total Assets|Company Total Assets Kala Pharmaceuticals|Cumulative Company Assets IRD (Opus Genetics Inc)|OKYO (okyopharma.com) - Aggregate Asset Value|Company Total Assets ADVM (Adverum Biotechnologies, Inc.)|Outlook Therapeutics Corp (OTLK) - Company Assets|CLSD: Cumulative Company Assets|Company Assets NovaBay Pharmaceuticals|KPRX: Company Total Assets|Company Assets Alimera Sciences, Inc. (ALIM)|Aggregate Company Assets Eyenovia Inc.|Guardion Health (GHSI) - Company Total Asset Base|Cumulative Company Assets OCUP (Ocuphire Pharma, Inc.)|Aggregate Company Assets OPT (opthea.com)